• MedX Health has revealed it has completed a pilot project with Health Partners for preventative healthcare management
  • The companies are partnering after the successful piloting of Medx’s DermSecure Screening Platform
  • The companies are aiming to roll out the service to provide dermatologist-assessed skin cancer screening to at-risk patients
  • Shares of MedX Health are up 40 per cent to C$0.035 as of 11:57 am ET

Shares of MedX Health (TSXV:MDX) received a boost on Wednesday morning after the release of skin cancer pilot project results in tandem with Health Partners.

In a news release, MedX Health stated it and Health Partners will be teaming up after the successful piloting of MedX’s DermSecure Screening Platform, which will aim to provide dermatologist-assessed skin cancer screening to at-risk patients.

“Health Partners is uniquely positioned to provide dermatologist-assessed skin cancer screening to at-risk patients right in their place of work as part of their regular employee health-plan assessments, “Mike Druhan, president of dermatology services at MedX Health, said in a statement. “The successful pilot with the MedX SIAscope devices and DermSecure platform demonstrated the efficiency and ease of access to this potentially life-saving service.”

Health Partners is the United Kingdom’s largest non-hospital private healthcare services provider with more than 2 million patients across 550 corporate, insurance and government clients.

Skin cancer has more than 220,000 cases diagnosed in the U.K. on an annual basis. Outdoor workers on average have a 60 per cent greater risk of developing skin cancer because of more sun exposure.

With its headquarters out of Ontario, MedX Health is a medical device and software company focused on skin health with its SIAscop on DermSecure telemedicine platform, utilizing its SIAscopy technology.

Shares of MedX Health are up 40 per cent to C$0.035 as of 11:57 am ET.

Join the discussion: Find out what everybody’s saying about this stock on the MedX Health Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.

More From The Market Online

Thomson Reuters expands its GenAI assistant

Thomson Reuters (TSX:TRI) has revealed the expanded vision for its professional-grade GenAI assistant, CoCounsel.

InZinc reports high-grade barite results from Indy project

InZinc Mining (TSXV:IZN) reports barite results from its 2022 diamond drilling at the Indy Project in British Columbia.
PyroGenesis - PyroGenesis' STP torch for refrigerant destruction, hydrocracking and heating.

PyroGenesis to help global mining leader lower emissions

PyroGenesis Canada (TSX:PYR) signs a contract with a global mining supplier to apply its electric plasma torches towards emissions reduction.

Canadian biotech stock investigates potential weight loss drugs

FSD Pharma Inc. (CSE:HUGE) is expanding its pipeline into metabolic and related disorders including weight loss and liver health.